AFAlexander Fichtner

Alexander Fichtner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander Fichtner has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Androgens Modulate Tumor–Immune Interactions in Testicular Germ Cell Tumors

    by Ida Hamann, Lucas Klaus, Patrick Fruth, Alexander Fichtner, Tobias J. Legler, Holger M. Reichardt, Fabian A. Gayer

    Background: The majority of testicular germ cell tumors (TGCT) are derived from the germ cell neoplasia in situ and arise after puberty in the local presence of high levels of testosterone. The seminoma subtype features a rich inflammatory infiltrate which impacts tumor progression but the role of testosterone in shaping tumor–immune interactions is yet unknown. Objective: We characterized androgen receptor and associated gene expression in the TGCT microenvironment and investigated the impact of dihydrotestosterone (DHT) on seminomatous tumor cells as well as stimulated T cells and monocytes. As an in vitro model of the seminoma microenvironment, cocultures of TCam‐2 cells with immune cell subtypes were analyzed in the presence of DHT. Material and Methods: Gene expression was analyzed in tumorous and nontumorous tissue specimens from TGCT patients and TGCT cell lines. Bulk and single‐cell RNA‐sequencing data were used for validation. T cells and monocytes were isolated from the blood of healthy individuals and either activated in vitro or cocultured with TCam‐2 cells. Proliferation and metabolic assays, quantitative RT‐PCR, flow cytometry, and ELISA were employed to assess the impact of DHT on tumor and immune cells. Results: Androgen receptor and related gene expression was demonstrated in tumorous tissue from patients, TGCT cell lines, and activated primary immune cells, which was supported by the analysis of published RNA‐seq data sets. DHT exerted only a minor effect on TCam‐2 cells, whereas hormone treatment markedly mitigated T cell and monocyte activation in a dose‐dependent manner. In addition, DHT modulated immune cell activity and selected features of TCam‐2 cells in T cell and monocyte cocultures serving as an in vitro model of the seminoma microenvironment. Discussion and Conclusion: Our results suggest that androgens present in tumorous testis of TGCT patients could impact tumor–immune interactions and thereby clinical outcome.

  • Postchemotherapy Germ Cell Tumor Phenotypes

    by Alexander Fichtner, Pailin Pongratanakul, Daniel Nettersheim, Felix Bremmer

    Germ cell tumors of the testis are the most common malignant tumor in young adults. The introduction of the use of cisplatin-based chemotherapy for testicular germ cell tumors from certain tumor stages in the 1970s has significantly improved the prognosis for these tumors. The resection of tumors that have undergone prior chemotherapy, usually in the area of retroperitoneal lymph node metastases or other sites of tumor metastasis, is an important part of the treatment for these patients. But prior treatment with chemotherapy might lead to the development of different special biological forms of germ cell tumors, including the so-called growing teratoma syndrome, somatic-type malignancies, sarcomatoid yolk-sac tumors, vasculogenic mesenchymal lesions, and trophoblastic tumors as well as unspecific changes. Pathologists should be aware of these different histopathologic changes associated with chemotherapy in germ cell tumor patients, as these might even occur years after the initial therapy. This article discusses the classic morphologic subtypes of germ cell tumors and the development of chemotherapy resistance and examines special morphologic forms and the diagnostic handling of postchemotherapy resection specimens.

  • Open Access

    Molecular pathology of testicular germ cell tumours: an update for practicing pathologists

    by Alexander Fichtner, Stefanie Zschäbitz, Daniel Nettersheim, Felix Bremmer

    Testicular tumours are a diverse group of tumours, but most cases fall into the category of testicular germ cell tumours (TGCT). TGCTs are classified as either derived from a germ cell neoplasia in situ (GCNIS) or unrelated to GCNIS. Based on the development, molecular alterations and onset of development, TGCTs can further be divided into three groups. Type I TGCTs include prepubertal‐type teratoma and yolk‐sac tumour. Type II TGCTs are the only GCNIS‐related tumours in this classification and include seminomas, embryonal carcinoma, choriocarcinoma, yolk‐sac tumour and teratoma of postpubertal type. Type III TGCTs only include spermatocytic tumours. While genetic alterations are helpful in the diagnostic routine, they have not yet been useful in determining treatment options, as targetable alterations are very rare. Type I TGCTs most commonly exhibit chromosomal aberrations and rarely display alterations related to the Wnt signalling pathway. A common molecular alteration in type II TGCTs is the presence of an isochromosome 12p or gain of 12p material. It is thought that the isochromosome 12p develops during the progression of a GCNIS to an invasive TGCT. Seminomas can also exhibit c‐Kit mutations or KRAS mutations. Alterations associated with the formation of a somatic‐type malignancy and/or the development of cisplatin resistance include TP53 mutations or MDM2 gene amplifications as well as epigenetic alterations. In advanced cases, some of these genes might be useful as targeted therapies (e.g. KRAS G12C or BRAF V600E), but as these mutations are rare, studies on larger groups of patients are not possible. Amplification of chromosome 9 including the DMRT1 gene, or Ras mutations is common in spermatocytic tumours. Overlapping molecular alterations, including those on chromosome 12, have recently been discovered in some type III TGCT. Tumour serum markers (e.g. alpha‐fetoprotein, beta‐subunit of human gonadotropin and microRNAs) are helpful in the diagnosis and for follow‐up analysis to detect recurrent disease or disease progression. This review article provides an overview of the current classification of testicular tumours and their molecular classification. Furthermore, it provides information on biomarkers that are helpful in the diagnostic setting. Additionally, we will provide guidance on how to examine a testicular tumour specimen histopathologically to reach an accurate diagnosis. Finally, we will outline the importance of the content of a histopathological report for the urologists and oncologists.


  • Die Lehre im Fach Pathologie in Deutschland

    by Alexander Fichtner, Christiane Kümpers

    Zusammenfassung Die Lehre des Fachs Pathologie an den 36 universitären pathologischen Instituten wird durch unterschiedliche curriculare Strukturen beeinflusst. Dabei variieren Lehrformate und Anzahl der Lehrveranstaltungsstunden teilweise deutlich, auch aufgrund struktureller Gegebenheiten an den einzelnen Standorten. Die Lehrinhalte erscheinen weitgehend kongruent. Die meisten ärztlichen MitarbeiterInnen sind an der Lehre beteiligt. Hierfür wünschen sich die WeiterbildungsassistentInnen eine gute Einarbeitung und Zeit für die Vorbereitung der Lehrveranstaltungen. Die InstitutsdirektorInnen gewichten die Lehre für sich persönlich ganz überwiegend als sehr wichtig bzw. wichtig, wohingegen ihre Zufriedenheit mit der Gesamtsituation der Lehre an den Standorten insgesamt nur mit „mäßig“ eingestuft wird. Die Studierenden sind mit der Lehre überwiegend zufrieden. Verbesserungsvorschläge beinhalten neben einer strukturierten, interdisziplinären und praxisbezogenen Lehre insbesondere Möglichkeiten zur Teilnahme an Obduktionen, Verwendung digitaler Formate (z. B. bei Vorlesungen, Mikroskopierkursen), genaueres Heranführen an die Beurteilung histopathologischer Befunde und eine bessere Darstellung der Tätigkeitsfelder in der Pathologie. Deutschlandweit sollte angestrebt werden, die Lehre stärker zu vereinheitlichen, um das Fach gemeinsam gegenüber Dekanaten und Prüfungsämtern besser zu vertreten. Zudem sollte eine Modernisierung von Lehrinhalten und -formen angestrebt werden, auch um das Fach für potenziellen Nachwuchs attraktiver zu gestalten.


  • Open Access

    Pathogenesis and pathobiology of testicular germ cell tumours: a view from a developmental biological perspective with guidelines for pathological diagnostics

    by Alexander Fichtner, Daniel Nettersheim, Felix Bremmer

    Testicular germ cell tumours (GCT) are divided into three different subtypes (types I–III) regarding to their developmental origin, histological differences and molecular features. Type I GCT develop from disturbed primordial germ cells and most commonly occur in children and young adolescents, which is why they are referred to as prepubertal GCT. Type II GCT develop from a non‐invasive germ cell neoplasia in situ (GCNIS) and show an isochromosome 12p (i12p) or gain of 12p material as a common and characteristic molecular alteration. Type III GCT originate from distorted postpubertal germ cells (e.g. spermatogonia) in adult patients and have changes on chromosome 9 with amplification of the DMRT1 gene. Type I GCT encompass prepubertal‐type teratomas and yolk‐sac tumours (YST). Type II GCT include seminoma, embryonal carcinoma, choriocarcinoma, postpubertal‐type teratoma and postpubertal‐type YST. Types I and II GCT both show similar morphology, but are separated from each other by the detection of a GCNIS and an i12p in type II GCT. For type II GCT it is especially important to detect non‐seminomatous elements, as these tumours have a worse biological behaviour and need a different treatment to seminomas. In contrast to types I and II GCT, type III tumours are equivalent to spermatocytic tumours and usually occur in elderly men, with few exceptions in young adults. The development of types I and II GCT seems to depend not upon driver mutations, but rather on changes in the epigenetic landscape. Furthermore, different pluripotency associated factors (e.g. OCT3/4, SOX2, SOX17) play a crucial role in GCT development and can be used as immunohistochemical markers allowing to distinguish the different subtypes from each other in morphologically challenging tissue specimens. Especially in metastatic sites, a morphological and immunohistochemical diagnostic algorithm is important to detect small subpopulations of each non‐seminomatous GCT subtype, which are associated with a poorer prognosis and need a different treatment. Furthermore, primary extragonadal GCT of the retroperitoneum or mediastinum develop from misguided germ cells during embryonic development, and might be challenging to detect in small tissue biopsies due to their rarity at corresponding sites. This review article summarises the pathobiological and developmental aspects of the three different types of testicular GCT that can be helpful in the histopathological examination of tumour specimens by pathologists.


  • Open Access

    Primary germ cell tumours of the mediastinum: A review with emphasis on diagnostic challenges

    by Alexander Fichtner, Alexander Marx, Philipp Ströbel, Felix Bremmer

    This article will review current aspects of the histopathological, immunohistochemical and molecular analysis of primary mediastinal germ cell tumours (PMGCTs) as well as their aetiological, epidemiological, clinical and therapeutic features. PMGCTs represent an important differential diagnosis in the spectrum of mediastinal tumours, and their diagnosis is usually made on small tissue samples from core needle biopsies in combination with diagnostic imaging and serum tumour markers. As in lymphomas, a small biopsy is often the only viable tumour sample available from these patients, as they receive chemotherapy prior to eventual surgical resection. Pathologists therefore need to apply an efficient combination of immunohistochemical markers to confirm the diagnosis of a PMGCT and to exclude morphological mimics.


  • Open Access

    The Subtype Identity of Testicular Cancer Cells Determines Their Immunostimulatory Activity in a Coculture Model

    by Fabian A. Gayer, Miriam Henkel, Juliane Luft, Sybille D. Reichardt, Alexander Fichtner, Tobias J. Legler, Holger M. Reichardt

    Testicular germ cell cancer (TGCC) is subdivided into several subtypes. While seminomatous germ cell tumors (SGCT) are characterized by an intensive infiltration of immune cells which constitute a pro-inflammatory tumor micromilieu (TME), immune cells in non-seminomatous germ cell tumors (NSGCT) are differently composed and less abundant. Previously, we have shown that the seminomatous cell line TCam-2 promotes T cell and monocyte activation in a coculture model, resulting in mutual interactions between both cell types. Here we set out to compare this feature of TCam-2 cells with the non-seminomatous cell line NTERA-2. Peripheral blood T cells or monocytes cocultured with NTERA-2 cells failed to secrete relevant amounts of pro-inflammatory cytokines, and significantly downregulated the expression of genes encoding activation markers and effector molecules. In contrast, immune cells cocultured with TCam-2 cells produced IL-2, IL-6 and TNFα, and strongly upregulated the expression of multiple pro-inflammatory genes. Furthermore, the expression of genes involved in proliferation, stemness and subtype specification remained unaltered in NTERA-2 cells during coculture with T cells or monocytes, indicating the absence of mutual interactions. Collectively, our findings uncover fundamental differences between SGCT and NSGCT in their capability to generate a pro-inflammatory TME, which possibly impacts the clinical features and prognosis of both TGCC subtypes.


  • Open Access

    A Coculture Model Mimicking the Tumor Microenvironment Unveils Mutual Interactions between Immune Cell Subtypes and the Human Seminoma Cell Line TCam-2

    by Fabian A. Gayer, Alexander Fichtner, Tobias J. Legler, Holger M. Reichardt

    Testicular germ cell cancer (TGCC) is the most common type of cancer in young men. Seminomas account for around half of them and are characterized by a pronounced infiltration of immune cells. So far, the impact of the tumor microenvironment (TME) on disease progression, especially the interaction of individual immune cell subtypes with the tumor cells, remains unclear. To address this question, we used an in vitro TME model involving the seminoma-derived cell line Tcam-2 and immune cell subsets purified from human peripheral blood. T cells and monocytes were strongly activated when individually cocultured with Tcam-2 cells as revealed by increased expression of activation markers and pro-inflammatory cytokines both on the mRNA and protein level. Importantly, the interaction between tumor and immune cells was mutual. Gene expression of pluripotency markers as well as markers of proliferation and cell cycle activity were upregulated in Tcam-2 cells in cocultures with T cells, whereas gene expression of SOX17, a marker for seminomas, was unaltered. Interestingly, the impact of monocytes on gene expression of Tcam-2 cells was less pronounced, indicating that the effects of individual immune cell subsets on tumor cells in the TME are highly specific. Collectively, our data indicate that seminoma cells induce immune cell activation and thereby generate a strong pro-inflammatory milieu, whereas T cells conversely increase the proliferation, metastatic potential, and stemness of tumor cells. Although the employed model does not fully mimic the physiological situation found in TGCC in vivo, it provides new insights potentially explaining the connection between inflammatory infiltrates in seminomas and their tendency to burn out and metastasize.


  • Open Access

    Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry

    by A. Fichtner, H. Bohnenberger, O. Elakad, A. Richter, C. Lenz, C. Oing, P. Ströbel, S. Kueffer, D. Nettersheim, F. Bremmer

    Purpose: Advanced testicular germ cell tumours (GCT) generally have a good prognosis owing to their unique sensitivity towards cisplatin-based chemotherapies. However, cisplatin-resistant GCT have a poor outcome. Further studies are mandatory to better understand resistance mechanisms and develop therapeutic strategies for refractory GCTs. Methods: Protein levels in cisplatin-resistant GCT cell lines of NTERA-2, NCCIT and 2102EP were analyzed by quantitative proteomic mass spectrometry (MS) in combination with stable isotope labelling by amino acids in cell culture (SILAC). Differentially abundant protein markers of acquired cisplatin resistance were validated by Western blotting. Comprehensive bioinformatical annotation using gene set enrichment analyses (GSEA) and STRING interaction analysis were performed to identify commonly affected pathways in cisplatin resistance and the data were compared to the GCT cohort of the ‘The Cancer Genome Atlas’. Results: A total of 4375 proteins were quantified by MS, 144 of which were found to be differentially abundant between isogenic resistant and sensitive cell line pairs (24 proteins for NTERA-2, 60 proteins for NCCIT, 75 proteins for 2102EP). Western blotting confirmed regulation of key resistance-associated proteins (CBS, ANXA1, LDHA, CTH, FDXR). GSEA revealed a statistically significant enrichment of DNA repair-associated proteins in all three resistant cell lines and specific additional processes for individual cell lines. Conclusion: High resolution MS combined with SILAC is a powerful tool and 144 significantly deregulated proteins were found in cisplatin-resistant GCT cell lines. Our study provides the largest proteomic in vitro library for cisplatin resistance in GCT, yet, enabling further studies to develop new treatment options for patients with refractory GCT.


  • Open Access

    Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry

    by Annika Richter, Alexander Fichtner, Jasmin Joost, Philipp Brockmeyer, Philipp Kauffmann, Henning Schliephake, Alexander Hammerstein‐Equord, Stefan Kueffer, Henning Urlaub, Thomas Oellerich, et al.

    The differentiation between a pulmonary metastasis and a newly developed squamous cell carcinoma of the lung in patients with prior head and neck squamous cell carcinoma (HNSCC) is difficult due to a lack of biomarkers but is crucially important for the prognosis and therapy of the affected patient. By using high‐resolution mass spectrometry in combination with stable isotope labelling by amino acids in cell culture, we identified 379 proteins that are differentially expressed in squamous cell carcinomas of the lung and the head and neck. Of those, CAV1, CAV2, LGALS1, LGALS7, CK19, and UGDH were tested by immunohistochemistry on 194 tissue samples (98 lung and 96 HNSCCs). The combination of CAV1 and LGALS7 was able to distinguish the origin of the squamous cell carcinoma with high accuracy (area under the curve 0.876). This biomarker panel was tested on a cohort of 12 clinically classified lung tumours of unknown origin after HNSCC. Nine of those tumours were immunohistochemically classifiable.